South Korea FFPE Tissue Samples for Genomics Study and Analysis Market Size, Share, Growth, and Industry Analysis, By Sample Type (Blocks, Slides, Scrolls, Curls ), By Nucleic Acid Type (Downstream Application) (DNA-based Genomic Analysis Whole Genome Sequencing (WGS) Whole Exome Sequencing (WES) CNV/SNP Analysis qPCR-based Genotyping, RNA-based Genomic Analysis Transcriptome Profiling mRNA Sequencing miRNA Sequencing Gene Fusion Studies ) and Forecast, 2026-2034

South Korea FFPE Tissue Samples for Genomics Study and Analysis Market Trends

NGS-Based Tumor Profiling Is Expanding the Utility of Archived Tissue

South Korea's clinical genomics infrastructure continues shifting toward high-throughput sequencing and standardized tumor profiling. HIRA reported 81 approved institutions for NGS-based genetic panel testing in the second half of 2025, demonstrating an established nationwide clinical testing network. Korea has reimbursed NGS-based genetic testing since 2017, and clinical recommendations identify sequencing as increasingly important for actionable alterations, pathological diagnosis, resistance analysis, and biomarker assessment.

Regulatory infrastructure is developing alongside laboratory adoption. On December 31, 2025, the Ministry of Food and Drug Safety issued guidance specifically addressing approval and review considerations for NGS-based tumor-profiling in-vitro diagnostic devices. HIRA subsequently scheduled new and renewal institutional applications during January 12–30, 2026. These developments strengthen demand for reproducible FFPE extraction, library preparation, sequencing, and bioinformatics workflows across DNA and RNA applications.

South Korea FFPE Tissue Samples for Genomics Study and Analysis Market Drivers

Precision Oncology and Institutional NGS Capacity Accelerate FFPE Utilization

Cancer molecular profiling remains a principal demand catalyst because FFPE tissue is routinely retained following histopathology and can subsequently support mutation, copy-number, fusion, and expression analysis. South Korea had 81 HIRA-approved NGS panel-testing institutions in the second half of 2025, while the national reimbursement pathway has supported clinical NGS since 2017. The expanding institutional base increases utilization of archived blocks and sections across multi-gene panels, targeted sequencing, and biomarker workflows.

South Korea FFPE Tissue Samples for Genomics Study and Analysis Market Restraints

Formalin-Induced Molecular Damage Limits Sequencing Yield and Reproducibility

FFPE preservation can fragment nucleic acids, introduce sequence artifacts, and reduce RNA integrity, creating workflow constraints compared with fresh or frozen specimens. Laboratories therefore require additional extraction optimization, quality thresholds, controls, and bioinformatics filtering. With 81 approved NGS testing institutions reported during 2025 and expanding regulatory scrutiny of tumor-profiling assays, standardization becomes increasingly important as clinical testing volumes broaden.

South Korea FFPE Tissue Samples for Genomics Study and Analysis Market Opportunities

Archived Tissue Banks Create a Scalable Resource for Retrospective Genomic Research

Large pathology archives allow researchers to connect historical clinical outcomes with molecular characteristics without prospectively collecting every specimen. The opportunity extends across WGS, WES, CNV/SNP analysis, qPCR, transcriptomics, mRNA sequencing, miRNA sequencing, and fusion studies. South Korea's network of 81 approved NGS panel institutions in 2025, combined with formal MFDS tumor-profiling guidance issued at year-end 2025, provides an increasingly structured environment for translating retrospective tissue analysis into clinical and research programs.

Challenges in South Korea FFPE Tissue Samples for Genomics Study and Analysis Market

Pre-Analytical Variability Complicates Multi-Institution Genomic Standardization

Differences in fixation duration, paraffin processing, storage age, tumor cellularity, extraction protocols, and sequencing platforms can produce variable genomic outputs from otherwise comparable specimens. This issue becomes operationally important across a network of 81 approved NGS panel-testing institutions. Regulatory guidance introduced in December 2025 further emphasizes the importance of consistent validation and performance assessment as tumor profiling expands across multiple laboratories and assay designs.

South Korea FFPE Tissue Samples for Genomics Study and Analysis Market Segmentation

The market is segmented by sample type, nucleic acid type, technology, application, and end user. In 2026, blocks dominate sample formats with approximately 31.3%, while DNA-based genomic analysis commands approximately 63.3% of downstream nucleic-acid revenue.

By Sample Type

Blocks represent the largest category, valued at USD 3.90 million in 2026 and projected to reach USD 5.95 million by 2034 at a 5.43% CAGR. Their 2026 contribution is approximately 31.3%, ahead of slides at USD 2.94 million and scrolls at USD 2.11 million.

Sections are the fastest-growing supplied sample category at a 5.89% CAGR, rising from USD 1.11 million in 2026 to USD 1.76 million by 2034. Other cores and punches grow at 5.64%, curls at 5.57%, slides at 5.55%, and scrolls at 5.39%.

By Nucleic Acid Type

DNA-based genomic analysis is the largest downstream category at USD 7.90 million in 2026, equivalent to approximately 63.3% of the USD 12.48 million nucleic-acid total. It is forecast to reach USD 12.34 million by 2034 at a 5.74% CAGR and includes WGS, WES, CNV/SNP analysis, and qPCR genotyping.

RNA-based genomic analysis accounts for USD 4.58 million in 2026 and reaches USD 6.98 million in 2034 at a 5.42% CAGR. Its workflows include transcriptome profiling, mRNA sequencing, miRNA sequencing, and gene-fusion studies.

By Technology

NGS is positioned as the principal high-throughput platform, supported by South Korea's clinical tumor-profiling infrastructure. Other technologies include microarrays, PCR/qPCR, digital PCR, Sanger sequencing, and Nanostring platforms. The 81 approved NGS panel-testing institutions reported in 2025 demonstrate substantial clinical sequencing infrastructure.

Technology selection varies with nucleic-acid quality, target breadth, turnaround requirements, and analytical sensitivity. Targeted PCR can support focused biomarkers, while NGS enables simultaneous evaluation of numerous genomic alterations and increasingly supports precision-oncology workflows.

By Application

Cancer genomics is the principal application environment because FFPE material is generated routinely through biopsy and surgical pathology. Other applications include infectious-disease genomics, neurological genomics, rare-disease research, pharmacogenomics, biomarker validation, and population-health studies.

Clinical recommendations in Korea describe NGS as important for actionable mutation identification, pathological diagnosis, resistance mechanisms, and biomarker assessment. This expanding scope supports progressively broader use of preserved specimens across translational and clinical genomics.

By End User

Academic institutes, CROs, biotechnology and biopharmaceutical companies, hospitals, diagnostic laboratories, biobanks, and tissue repositories constitute the core customer groups. Hospitals and diagnostic laboratories benefit particularly from the established 81-institution NGS testing infrastructure reported during 2025.

Academic institutes and biobanks additionally benefit from retrospective cohort studies, while CROs and biopharmaceutical companies utilize archived specimens for biomarker discovery, translational research, trial stratification, and assay validation.

South Korea FFPE Tissue Samples for Genomics Study and Analysis Market Counties Outlook

South Korea constitutes 100% of the geographic scope of this country-level assessment. The national sample-type market is USD 12.46 million in 2026 and is forecast at USD 19.17 million in 2034. Within that total, blocks contribute approximately 31.3%, slides 23.6%, and scrolls 16.9%, collectively representing about 71.8% of 2026 sample-format revenue.

Activity is concentrated around major metropolitan healthcare and research ecosystems, particularly Seoul and the broader capital region, alongside major clinical centers in Busan, Daegu, Daejeon, Gwangju, and other provincial hubs. No supplied dataset provides defensible subnational revenue percentages; therefore, county or metropolitan shares are not fabricated. Nationally, DNA workflows contribute approximately 63.3% of the 2026 downstream total and RNA workflows approximately 36.7%.

Top players in South Korea FFPE Tissue Samples for Genomics Study and Analysis Market

1. Thermo Fisher Scientific
2. QIAGEN
3. Illumina
4. Roche
5. Agilent Technologies
6. Bio-Rad Laboratories
7. Leica Biosystems
8. Merck KGaA
9. Takara Bio
10. Promega Corporation
11. NanoString Technologies
12. Oxford Nanopore Technologies
13. Bioneer Corporation
14. Macrogen
15. GC Genome

Top Two Companies

• Thermo Fisher Scientific:The company has broad positioning across nucleic-acid extraction, PCR/qPCR, sequencing preparation, instruments, reagents, and oncology research workflows, creating exposure to multiple stages of FFPE genomic analysis. The supplied market dataset does not contain company-level revenue or market-share percentages, and reliable public sources do not establish a defensible South Korea FFPE-specific percentage; therefore, a fabricated share is not assigned. Competitive positioning instead reflects portfolio breadth across workflows serving laboratories handling DNA and RNA from preserved tissues.
• QIAGEN:QIAGEN is strongly positioned around sample preparation, FFPE DNA/RNA extraction, quality control, PCR, digital PCR, and molecular testing workflows. These capabilities align with a South Korean downstream market in which DNA analysis represents approximately 63.3% and RNA analysis approximately 36.7% of supplied 2026 nucleic-acid revenue. Company-specific South Korean FFPE revenue percentages are not disclosed in the supplied dataset, so no unsupported competitive percentage is presented.

Recent Developments in South Korea FFPE Tissue Samples for Genomics Study and Analysis Market

• 2026:HIRA scheduled applications for new and renewing NGS-based genetic-panel testing institutions from January 12 to January 30, reinforcing the formal clinical sequencing framework.
• 2025:MFDS issued dedicated guidance for approval and review of NGS-based tumor-profiling in-vitro diagnostic medical devices on December 31.
• 2025:HIRA reported 81 approved institutions performing NGS-based genetic panel testing during the second half of the year.
• 2025:South Korea maintained a regulated conditional-benefit framework for NGS genetic panel testing, supporting institutional renewal and quality oversight.

Research Methodology

The assessment uses the supplied mandatory numerical tables as the primary quantitative source for 2025 baseline values, 2026 estimates, 2034 forecasts, segment contributions, and CAGR calculations. Percentage contributions were calculated directly from supplied totals; for example, USD 3.90 million of USD 12.46 million produces approximately 31.3% for blocks in 2026, while USD 7.90 million of USD 12.48 million produces approximately 63.3% for DNA-based analysis. Secondary qualitative validation incorporates South Korean regulatory and clinical sources, including MFDS, HIRA, and published Korean oncology recommendations. Where company-level or subnational percentage data were unavailable, values were not fabricated.